The raise of $20+ million post phase II trial, and Tattarang as a sub holder (along with Sinclair as a genuine leader in the field) did not scream red flags but obviously there was something there we all missed
Ann: Invex to close IIH Evolve Phase III Clinical Trial, page-39
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.411M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.6¢ | 888 | 1 |
View Market Depth
| Last trade - 16.12pm 16/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable